stoxline Quote Chart Rank Option Currency Glossary
  
Trevena, Inc. (TRVN)
0.5611  -0.007 (-1.25%)    02-23 15:59
Open: 0.5781
High: 0.58
Volume: 66,132
  
Pre. Close: 0.5682
Low: 0.54
Market Cap: 9(M)
Technical analysis
2024-02-23 4:39:59 PM
Short term     
Mid term     
Targets 6-month :  0.77 1-year :  0.86
Resists First :  0.66 Second :  0.74
Pivot price 0.58
Supports First :  0.54 Second :  0.44
MAs MA(5) :  0.56 MA(20) :  0.59
MA(100) :  0.61 MA(250) :  0.79
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  19.9 D(3) :  16.2
RSI RSI(14): 36.9
52-week High :  3.27 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ TRVN ] has closed above bottom band by 19.3%. Bollinger Bands are 37.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.58 - 0.58 0.58 - 0.59
Low: 0.53 - 0.53 0.53 - 0.54
Close: 0.55 - 0.56 0.56 - 0.57
Company Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Headline News

Mon, 26 Feb 2024
Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com - AmericanBankingNEWS

Fri, 02 Feb 2024
Trevena Inc Elevates Barry Shin to Executive VP and CFO - TipRanks.com - TipRanks

Wed, 27 Dec 2023
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise - Barron's

Wed, 15 Nov 2023
Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript - Yahoo Finance

Wed, 31 May 2023
5 Hot Penny Stocks To Watch With Big News This Week - Penny Stocks

Mon, 08 May 2023
Best Penny Stocks To Buy Now? 4 To Watch Before May CPI Data - Penny Stocks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 17 (M)
Held by Insiders 1.499e+007 (%)
Held by Institutions 0.6 (%)
Shares Short 71 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.416e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -4 %
Return on Assets (ttm) 903.8 %
Return on Equity (ttm) -44.9 %
Qtrly Rev. Growth 3.21e+006 %
Gross Profit (p.s.) 0
Sales Per Share -205.21
EBITDA (p.s.) 0
Qtrly Earnings Growth -2.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -38 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 2.75
Stock Dividends
Dividend 0
Forward Dividend 43790
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android